Principle Investors of Hydra Biosciences

Principal investors include:

Abingworth is a long-established venture capital firm specializing in unquoted and life science biomedical companies. With offices in London, Cambridge (UK), Menlo Park and Boston, Abingworth is active on both sides of the Atlantic and, in the past fifteen years, has backed more than 80 developing life science/medical businesses. The majority of these have gone on to public offerings or have merged or been acquired by leading companies in the industry. Abingworth has funds under management of over $700 million. More information regarding Abingworth can be obtained at www.abingworth.com.

Advanced Technology Ventures was founded in 1979 and is a technology-oriented venture firm focused on investments in communications, Internet infrastructure, software & services and healthcare. ATV has $750 million under management and maintains offices in the Silicon Valley and Boston technology corridors. More information regarding ATV can be obtained at www.atvcapital.com.

Biogen Idec New Ventures is Biogen Idec's corporate venture group, which was formed in 2004 with an initial commitment of $100 million for strategic investments in emerging biotech companies. Our strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. We want our equity investment to be the basis for further relationship building with company founders, their companies and their other investors. Once investments are made, we look forward to staying engaged with the portfolio companies and providing assistance through our global resources and experience to help ensure their success. More information regarding Biogen Idec New Ventures can be obtained at www.biogenidec.com/site/new-ventures.html.

BioVentures   invests in companies conducting high-quality life-science research with clear commercial application and a strong proprietary position. Our strategy is to select companies with both potentially valuable science and a well-defined development pathway. Successive experiments in the laboratory or in the clinic and the meeting of specific operational goals should add predictable and significant incremental value to our investment. Company management should be capable of meeting these targets and should understand the relationship between scientific success and value enhancement. More information regarding BioVentures Investors can be obtained at
www.bioventuresinvestors.com.

Lilly Ventures, a stand-alone venture capital firm with its roots in the scientific tradition of Eli Lilly and Company, seeks to invest in great companies with compelling life science innovations and outstanding management teams in North America and Europe. Given the depth and breadth of the operational experience of our team, we actively partner with the management teams and co-investors of our portfolio companies at the seed, early and expansion stages. Lilly Ventures targets investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline that can have a meaningful impact on patient outcomes. More information regarding Lilly Ventures can be obtained at www.lillyventures.com.

MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. It was created in 2002 to leverage MedImmune's expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies. MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to Astra Zeneca and MedImmune, including infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system disorders, and gastrointestinal disease. We are modality agnostic, investing in biologics, small molecules, and vaccines. More information regarding MedImmune Ventures can be obtained at www.medimmune.com/ventures/overview.asp.

New Enterprise Associates (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same basic principles: support their entrepreneurs, provide an excellent return to their limited partners and practice their profession with high standards and respect. Practicing classic venture capital for over 25 years, NEA focuses on early stage investments, playing an active role in assisting management to build companies of lasting value. With $6 billion under management, NEA's experienced management team has invested in over 500 companies, of which more than 145 have gone public and more than 185 have been acquired. NEA has offices in Reston, Virginia, Menlo Park, California and Baltimore, Maryland. More information regarding NEA can be obtained at www.nea.com.

Polaris Venture Partners is a partnership of experienced venture capital investors and technology executives whose mission is to identify and invest in seed, first round, and early stage information technology and life sciences companies with exceptional promise and help them grow into market-leading companies. Polaris also is committed to providing growth equity and shareholder liquidity to established companies in a broader range of industries. Polaris has offices on both coasts: Boston, Massachusetts, and Seattle, Washington. We currently have over $2 billion under management and investments in more than 60 companies. More information regarding Polaris can be obtained at www.polarisventures.com.